highly significantp = 0.00097
For the Ipi-N cohort, this increase in TCR.strong score was highly significant (p = 0.00097) in those with evidence of clinical benefit, which was not captured by the T cell activation metric ( Figure 7 D).
For the Ipi-N cohort, this increase in TCR.strong score was highly significant (p = 0.00097) in those with evidence of clinical benefit, which was not captured by the T cell activation metric ( Figure 7 D).
Analysis of the TCR.strong metric in the Ipi-N cohort of patients showed increases in those with clinical responses (p = 0.0105) and a strong trend in patients from the Ipi-P group (p = 0.1531, Figure 7 C).